Dxcover
From Wikipedia, the free encyclopedia
| Company type | Dxcover Limited |
|---|---|
| Industry | Natural Science and Engineering |
| Founded | 2016 |
| Founder | Matthew James Baker, David S. Palmer, Holly J. Butler, Mark Hegarty |
| Headquarters | , Scotland |
Area served | UK, EU, US |
| Products | Infrared Spectroscopy, Diagnostic Algorithm, Disease Prediction, Cancer Screening |
Number of employees | 24 |
| Website | www |
Dxcover Limited is a Scottish company which was founded on 16 May 2016.[1] It is based in Glasgow, UK. It combines novel hardwares with artificial intelligence algorithms. Patients' blood samples are analysed by scientists to detect the presence of diseases. It is a clinical stage liquid biopsy company[2] and uses artificial intelligence algorithms for early detection of cancers and other diseases to improve survival rates. Its marketplaces are located in the US, UK and EU.[3] The company aims to detect early stage (Stage I and Stage II) of cancers.[4][5]
The company was previously named as ClinSpec Diagnostics Limited between 16 May 2016 and 26 April 2021.[1] It is spun out from the University of Strathclyde, Glasgow. After that, it is rebranded as Dxcover Limited in 2021.[1]
